Vertex reported phase‑3 Rainier results for povetacicept showing a robust placebo‑adjusted reduction in urine protein‑to‑creatinine ratio (~49.8% at interim), and the company is preparing a BLA for accelerated approval. Analysts called the effect size the largest seen to date in IgA nephropathy trials and flagged strong commercial potential. Vertex plans to file to the FDA promptly, citing the Rainier dataset; the program positions povetacicept to compete with other BAFF/APRIL pathway agents and could reshape the IgAN treatment landscape pending regulatory review.